Evidence map›Paper›PMID 41186228›Full record

Trial reportAntimicrobial agents and chemotherapy2025

Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection.

Anna Maria Geretti, Alexandre Sostelly, Simon Buatois, Sijie Lu, Annabelle Lemenuel, Gemma Attley, Martin Bopst, Rubén Alvarez-Sánchez, Henrik Mueller, Edward Gane

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna Maria Geretti *Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Alexandre Sostelly *Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Simon BuatoisRoche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Sijie LuRoche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.
Annabelle LemenuelRoche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Gemma AttleyRoche Pharma Research and Early Development, Roche Innovation Center New York, , Little Falls, New Jersey, USA.ORCID 0009-0000-3382-6747
Martin BopstRoche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Rubén Alvarez-SánchezRoche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Henrik MuellerRoche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Edward GaneAuckland Clinical Studies, Auckland, New Zealand.

Funding

F. Hoffmann-La Roche
6 · The paper itself

Abstract

Poly(A) RNA polymerases D5 and D7 (PAPD5, PAPD7) are host factors that stabilize hepatitis B virus (HBV) RNA transcripts. RO7239958, a liver-targeted locked nucleic acid (LNA) antisense oligonucleotide (ASO), induces intracellular degradation of PAPD5- and PAPD7-encoding messenger RNAs (mRNAs). This first-in-human study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7239958 in healthy volunteers and adults with chronic hepatitis B (CHB) receiving standard-of-care antiviral therapy. Forty healthy volunteers were randomized (4:1) to single ascending subcutaneous doses of RO7239958 (0.1, 0.3, 1.0, or 1.5 mg/kg) or placebo. Based on a population PK model built to predict liver exposure, two parallel CHB cohorts (

Indexed as

Antiviral AgentsHepatitis B, ChronicOligonucleotidesOligonucleotides, AntisenseAdultDouble-Blind MethodFemaleHealthy VolunteersHepatitis B virusHumansLiverMaleMiddle AgedYoung AdultAntiviral AgentsOligonucleotidesOligonucleotides, Antisensecurehepatitis B viruslocked-nucleic acidPAPD5PAPD7pharmacodynamicspharmacokineticsRO7239958single-stranded oligonucleotideTENT4ATENT4B

Identifiers

PMID41186228
PMCPMC12691668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.